Short Communication

Circulating tumour cells are associated with increased risk of venous thromboembolism in metastatic breast cancer patients

M Mego^{1,2,3}, U De Giorgi^{1,2}, K Broglio⁴, S Dawood², V Valero², E Andreopoulou², B Handy², JM Reuben¹ and M Cristofanilli^{*,2}

¹Department of Hematopathology, University of Texas, MD Anderson Cancer Center, Houston, TX, USA; ²Department of Breast Medical Oncology, Morgan Welch Inflammatory Breast Cancer Research Program and Clinic, University of Texas, MD Anderson Cancer Center, Houston, TX, USA;

³Department of Medical Oncology, Comenius University, School of Medicine, Bratislava, Slovakia; ⁴Department of Biostatistics, University of Texas, MD Anderson Cancer Center, Houston, TX, USA

BACKGROUND: Cancer is a risk factor for venous thromboembolism (VTE). Circulating tumour cells (CTCs) are an independent predictor of survival in metastatic breast cancer (MBC) patients. The aim of this study was to test the hypothesis that CTCs are associated with the risk of VTE in MBC patients.

METHODS: This retrospective study included 290 MBC patients treated in the MD Anderson Cancer Center from January 2004 to December 2007. Circulating tumour cells were detected and enumerated using the CellSearch system before starting new lines of therapy.

RESULTS: At a median follow-up of 12.5 months, 25 patients experienced VTE and 53 patients died without experiencing thrombosis. Cumulative incidence of thrombosis at 12 months was 8.5% (95% confidence interval (CI) = 5.5%, 12.4%). Patients with CTCs ≥ 1 and ≥ 5 had a higher incidence of VTE compared with patients with 0 and <5 CTCs (12-month estimate, 11.7 and 11.6% vs 3 and 6.6%; $P=0.006$ and $P=0.076$, respectively). In the multivariate model, patients with CTCs ≥ 1 had a hazard ratio of VTE of 5.29 (95% CI = 1.58, 17.7, $P=0.007$) compared with patients with no CTCs.

CONCLUSION: These results suggest that CTCs in MBC patients are associated with increased risk of VTE. These patients should be followed up more closely for the risk of VTE.

British Journal of Cancer (2009) 101, 1813–1816. doi:10.1038/sj.bjc.6605413 www.bjcancer.com

Published online 3 November 2009

© 2009 Cancer Research UK

Keywords: circulating tumour cells; venous thromboembolism

Cancer is a well-recognised risk factor for venous thromboembolism (VTE). It has been shown that 5–10% of all cancer patients will develop VTE during the course of the disease (Silverstein *et al*, 1998). Evidence suggests that the absolute risk depends on the tumour type, the stage or extent of the cancer, and treatment with antineoplastic agents (Silverstein *et al*, 1998).

Venous thromboembolism following breast cancer chemotherapy is common. In early breast cancer, VTE occurs in 5–10% of patients receiving chemotherapy (Weiss *et al*, 1981; Levine *et al*, 1988; von Tempelhoff *et al*, 1996), and it rises up to 18% in advanced breast cancer with 9% mortality (Goodnough *et al*, 1984; Kirwan *et al*, 2008).

Circulating tumour cells (CTCs) are an independent predictor of progression-free survival (PFS) and overall survival (OS) in patients with metastatic breast cancer (MBC) (Cristofanilli *et al*, 2004). Superior survival among patients with <5 CTCs was observed regardless of histology, hormone receptor and HER2/neu status, sites of first metastases, or whether the patient had relapse

or *de novo* metastatic disease (Cristofanilli *et al*, 2004; Dawood *et al*, 2008).

Increased CTC count and VTE are poor prognostic factors in MBC and are linked to inferior survival. In this retrospective study, we tested the hypothesis that CTCs are associated with the risk of VTE in MBC patients.

PATIENTS AND METHODS

Study patients

This study was conducted using the MD Anderson Cancer Center medical records database. The retrospective study was approved by the institutional review board and a waiver of consent form was granted. A population of consecutive MBC patients with at least one measurement of CTC before starting a new line of therapy from January 2004 to December 2007 was eligible. In addition, patients were not excluded on the basis of whether they underwent treatment with any particular form of chemotherapy, hormonal therapy, or biological therapy. Patients on prophylactic or therapeutic anticoagulation therapy including warfarin 1 mg per day or equivalent for port-a-catheter thromboprophylaxis, low molecular weight heparin, or unfractionated heparin were excluded from the analysis. Patients with concurrent malignancy

*Correspondence: Dr M Cristofanilli, Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Box 1354, 1515 Holcombe Boulevard, Houston, TX 77030, USA; E-mail: mcristof@mdanderson.org

Revised 6 October 2009; accepted 9 October 2009; published online 3 November 2009

other than non-melanoma skin cancer in the previous 5 years were excluded as well. In all, patient data regarding age, tumour histology, hormone receptor status, HER2 status, type and number of metastatic sites, systemic therapy, history of VTE, comorbidities (hypertension, diabetes mellitus), and concomitant therapy were also recorded and compared with risk of VTE.

Definition of the events

All venous thrombosis and/or pulmonary embolism in the presence of unequivocal medical documentation were classified as events. A patient was considered to have had a VTE if the event was clinically apparent and confirmed by diagnostic studies. Cases of superficial phlebitis and cases of secondary thrombosis attributed to superior vena cava syndrome and/or bulky abdominal lymphadenopathy were not classified as events and were excluded from the analysis.

Detection of CTCs in peripheral blood

The CellSearch system (Veridex Corporation, Warren, NJ, USA) was used to detect CTCs in 7.5 ml of whole peripheral blood. Samples were subject to enrichment with anti-EpCAM-coated beads. Circulating tumour cells were defined as nucleated cells lacking CD45 but expressing cytokeratins 8, 18, or 19.

Statistical analysis

Baseline CTCs were defined as the earliest CTC measurement taken before the start of a new line of therapy. Time to thrombosis was calculated from the date of baseline CTC assessment to the date of thrombosis or last follow-up. We calculated the cumulative incidence of thrombosis according to the method previously described (Gray, 1988). We considered baseline CTCs as a continuous measurement, dichotomised at 1 and at 5. The cutoff at 1 was chosen because it has been investigated in other settings such as primary breast cancer (Cristofanilli *et al*, 2004; Lang *et al*, 2009). The cutoff at 5 has been established as prognostic for PFS and OS for MBC patients in other studies.

Analyses were repeated considering patients who died before experiencing a thrombosis as censored at their date of death and estimating survival from thrombosis according to the Kaplan–Meier method. Results were similar. Therefore, we used Cox proportional hazards models both to assess CTCs as continuous measurements and to determine the association between CTCs and thrombosis after adjustment for other patient and disease characteristics.

Analyses were conducted in R2.4.0 with the contributed package, cmprsk (Gray, 2004; R Development Core Team, 2006). *P*-values <0.05 were considered statistically significant.

RESULTS

We identified 290 patients who satisfied the study eligibility criteria and were included in this analysis. Patient characteristics are shown in Table 1.

A total of 25 patients experienced a thrombosis and 53 patients died without experiencing a thrombosis. Estimates of the cumulative incidence of thrombosis are shown in Table 2. Among all patients, the cumulative incidence of thrombosis at 12 months was 8.5% (95% confidence interval (CI) = 5.5%, 12.4%). There was no association between baseline CTCs and thrombosis when baseline CTCs were considered as continuous in a univariate Cox proportional hazards model (hazards ratio (HR) = 1.0, 95% CI = 0.994, 1.00, *P* = 0.73). When baseline CTCs were considered dichotomised at 1, patients with CTCs ≥ 1 had four times higher incidence of thrombosis compared with patients with CTC = 0

Table 1 Patient characteristics (*n* = 290)

	N	Percent
Median age; years (range)	54 (23–84)	
Median baseline CTC (range)	2 (0–1780)	
Line of therapy		
1	123	42.41
2 or more	167	57.59
Estrogen and progesterone receptor		
Positive for both	192	66.21
Negative for either	98	33.79
HER2/neu amplified		
No	227	78.28
Yes	62	21.38
Unknown	1	0.34
Inflammatory breast cancer		
No	222	76.55
Yes	68	23.45
Visceral metastasis		
No	109	37.59
Yes	181	62.41
Bone metastasis		
No	88	30.34
Yes	202	69.66
Number of sites of metastasis		
1	100	34.48
2	89	30.69
3	55	18.97
≥ 4	46	15.86
Chemotherapy		
No	36	12.41
Yes	254	87.59
Bevacizumab-based therapy	60	20.69
Hormonal therapy		
No	164	56.55
Yes	126	43.45
Erythropoietin-stimulating agents		
No	256	88.28
Yes	34	11.72
Port-a-catheter and/or central venous device		
No	211	72.76
Yes	79	27.24
Arterial hypertension		
No	188	64.83
Yes	102	35.17
Diabetes mellitus		
No	255	87.93
Yes	35	12.07

Abbreviation: CTC = circulating tumour cells.

(12-month estimate 3.0 vs 11.7%, *P* = 0.006). Patients with CTCs ≥ 1 have inferior survival compared with patients with CTC = 0 (HR = 0.54, 95% CI = 0.33–0.89, *P* = 0.03). When patients were considered grouped according to CTCs ≥ 5 vs CTCs < 5, patients with fewer CTCs had a lower incidence of thrombosis compared with patients with more CTCs; however, statistical significance was not attained (6.6 vs 11.6%, *P* = 0.076).

We considered the baseline CTC measurement dichotomised as 0 vs 1 or more in a multivariable Cox proportional hazards model

Table 2 Estimates of the cumulative incidence of thrombosis

	N	No of thrombosis events	12-Month estimate (percent)	95% Confidence interval	P-value
All	290	25	8.5	(5.5, 12.4)	—
Baseline CTC					
0	108	3	3.0	(0.8, 7.9)	0.006
≥1	182	22	11.7	(7.3, 17.3)	
Baseline CTC					
<5	177	11	6.6	(3.3, 11.4)	0.076
≥5	113	14	11.6	(6.3, 18.6)	
Age (years)					
<50	100	10	8.9	(4.1, 15.9)	0.552
>50	190	15	8.3	(4.7, 13.2)	
Line of therapy					
1	123	6	3.3	(1.1, 7.8)	0.027
≥2	167	19	12.8	(7.8, 19.1)	
Estrogen and progesterone receptor					
Positive for both	192	14	6.4	(3.4, 10.8)	0.188
Negative for either	98	11	12.8	(6.7, 21.0)	
HER2/neu amplified					
No	227	20	8.4	(5.1, 12.8)	0.900
Yes	62	5	8.8	(3.2, 18.1)	
Inflammatory breast cancer					
No	222	17	7.9	(4.7, 12.1)	0.234
Yes	68	8	11.1	(4.3, 21.3)	
Visceral metastasis					
No	109	2	2.0	(0.4, 6.3)	0.002
Yes	181	23	12.3	(7.8, 18.0)	
Bone metastasis					
No	88	6	8.6	(3.4, 16.9)	0.547
Yes	202	19	8.6	(5.1, 13.2)	
Number of sites of metastasis					
1	100	3	3.53	(0.9, 9.2)	0.002
2 or 3	144	11	7.69	(3.9, 13.2)	
≥4	46	11	21.07	(10.2, 34.5)	
Chemotherapy					
No	36	3	5.6	(1.0, 16.5)	0.934
Yes	254	22	8.8	(5.6, 13.0)	
Bevacizumab-based therapy					
No	230	20	8.1	(4.9, 12.4)	0.999
Yes	60	5	10.0	(3.5, 20.5)	
Hormonal therapy					
No	164	19	11.9	(7.2, 18.0)	0.037
Yes	126	6	4.2	(1.6, 8.9)	
Tamoxifen					
No	101	10	10.4	(5.3, 17.5)	0.177
Yes	38	1	0.0	—	
Aromatase inhibitors					
No	194	22	11.2	(7.0, 16.6)	0.016
Yes	96	3	3.2	(0.9, 8.3)	
Erythropoietin-stimulating agents					
No	256	24	9.3	(5.9, 13.6)	0.150
Yes	34	1	2.9	(0.2, 13.2)	

Table 2 (Continued)

	N	No of thrombosis events	12-Month estimate (percent)	95% Confidence interval	P-value
Port-a-catheter and/or central venous device					
No	211	17	7.9	(4.6, 12.4)	0.747
Yes	79	8	9.8	(4.2, 18.1)	
History of DVT/PE					
No	274	23	8.0	(5.1, 11.9)	0.672
Yes	16	2	14.6	(2.0, 38.7)	
Arterial hypertension					
No	188	19	9.1	(5.4, 13.9)	0.242
Yes	102	6	7.5	(3.0, 14.8)	
Diabetes mellitus					
No	255	22	8.5	(5.3, 12.6)	0.924
Yes	35	3	8.9	(2.2, 21.6)	

Abbreviations: DVT = deep vein thrombosis; PE = pulmonary embolism, CTC = circulating tumour cells.

to determine whether the association with thrombosis persisted after adjustment for other characteristics. After adjustment for these other terms, having at least one CTC was associated with 5.29 times the risk of thrombosis compared with patients with no CTC (95% CI = 1.58, 17.7, $P = 0.007$) (Table 3).

DISCUSSION

This large single centre retrospective study showed that CTCs are associated with increased risk of VTE in MBC patients. The risk is increased in patients with CTCs ≥ 1 before starting new line of therapy. Observed cumulative 12-month incidence of VTE in our patients was 8.5%, which is in concordance with data from literature. (Ottinger *et al*, 1995; Baron *et al*, 1998). We confirmed that the presence of visceral metastases, increased number of metastases, and subsequent lines of therapy are associated with increased risk of VTE. These factors mainly reflect advanced disease, with higher incidence of VTE at all.

In a prospective, multicentre study, the number of CTCs before chemotherapy was an independent predictor of PFS and OS in MBC patients. Although the threshold of 5 CTCs per 7.5 ml of blood has been shown to be prognostic for survival (Cristofanilli *et al*, 2004), in our study, any detectable CTCs were associated with increased risk for VTE as well as with increased risk of death. We also observed that MBC patients with CTCs ≥ 5 have a doubled risk of VTE compared with patients with CTCs < 5; however, this difference did not reach statistical significance.

There are several mechanisms that may explain this association (CTC and VTE). Increased CTC count is a marker of more aggressive disease with increased risk of VTE (Cristofanilli *et al*, 2004). Circulating tumour cells could be directly involved in coagulation activation as well. It is supposed that the direct toxic effect of anticancer treatment on cancer cells may lead to an increase in CTC fragments or microparticles with procoagulant activity (Dvorak *et al*, 1983). Circulating tumour cells could be involved in the activation of coagulation through the expression and release of tissue factors (TFs) (Davila *et al*, 2008). It was shown that TFs are overexpressed in cells with cancer stem cell phenotype (Milsom *et al*, 2007). At least the subgroups of CTCs are potential cancer stem cells (Reuben *et al*, 2007); therefore, CTCs could be an important source of TFs and could be involved directly in coagulation activation.

The main limitation of this trial is the retrospective nature of analysis. Therefore, the study results are only hypothesis

Table 3 Cox proportional hazards model

	Hazard ratio	Lower 95% CI	Upper 95% CI	P-value
Baseline CTC (≥ 1 vs 0)	5.29	1.58	17.70	0.007
Line of therapy (≥ 2 vs 1)	2.53	1.00	6.40	0.049
Number of metastatic sites (2 or 3 vs 1)	2.81	0.78	10.10	0.110
Number of metastatic sites (4 or 5 vs 1)	8.08	2.24	29.10	0.001

Abbreviations: CI = confidence interval; CTC = circulating tumour cells.

generating. Sample size, heterogeneous patient population, and heterogeneity of therapy might affect the study results. On the other hand, the majority of patients in our analysis were treated according to daily clinical practice, which might increase the generalisability of the results.

To our knowledge, this is the first study to assess the prognostic value of CTCs on the risk of VTE. Patients with MBC and any detectable CTCs are at increased risk for VTE. These patients should be followed more closely for the risk of VTE. Further research in this field is warranted, with prospective assessment of

coagulation status and its correlation with CTC count and clinical outcome.

ACKNOWLEDGEMENTS

Massimo Cristofanilli received a grant from the State of Texas Rare and Aggressive Breast Cancer Research Program. Michal Mego was supported by a UICC American Cancer Society International Fellowship for Beginning Investigators, ACSBI Award ACS/08/006.

REFERENCES

- Baron JA, Gridley G, Weiderpass E, Nyrén O, Linet M (1998) Venous thromboembolism and cancer. *Lancet* **351**: 1077–1080
- Cristofanilli M, Budd GT, Ellis MJ, Stopeck A, Matera J, Miller MC, Reuben JM, Doyle GV, Allard WJ, Terstappen LW, Hayes DF (2004) Circulating tumor cells, disease progression, and survival in metastatic breast cancer. *N Engl J Med* **351**: 781–791
- Davila M, Amirkhosravi A, Coll E, Desai H, Robles L, Colon J, Baker CH, Francis JL (2008) Tissue factor-bearing microparticles derived from tumor cells: impact on coagulation activation. *J Thromb Haemost* **6**: 1517–1524
- Dawood S, Broglio K, Valero V, Reuben J, Handy B, Islam R, Jackson S, Hortobagyi GN, Fritsche H, Cristofanilli M (2008) Circulating tumor cells in metastatic breast cancer: from prognostic stratification to modification of the staging system? *Cancer* **113**: 2422–2430
- Dvorak HF, Van DeWater L, Bitzer AM, Dvorak AM, Anderson D, Harvey VS, Bach R, Davis GL, DeWolf W, Carvalho AC (1983) Procoagulant activity associated with plasma membrane vesicles shed by cultured tumor cells. *Cancer Res* **43**: 4434–4442
- Goodnough LT, Saito H, Manni A, Jones PK, Pearson OH (1984) Increased incidence of thromboembolism in stage IV breast cancer patients treated with a five-drug chemotherapy regimen. A study of 159 patients. *Cancer* **54**: 1264–1268
- Gray RJ (1988) A class of K-sample tests for comparing the cumulative incidence of a competing risk. *Ann Stat* **16**: 1141–1154
- Gray RJ (2004) *cmprsk: Subdistribution Analysis of Competing Risks*. R package version 2.1-5. <http://www.r-project.org>, <http://biowww.dfci.harvard.edu/~gray>
- Kirwan CC, McDowell G, McCollum CN, Kumar S, Byrne GJ (2008) Early changes in the haemostatic and procoagulant systems after chemotherapy for breast cancer. *Br J Cancer* **99**: 1000–1006
- Lang JE, Mosalpuria K, Cristofanilli M, Krishnamurthy S, Reuben J, Singh B, Bedrosian I, Meric-Bernstam F, Lucci A (2009) HER2 status predicts the presence of circulating tumor cells in patients with operable breast cancer. *Breast Cancer Res Treat* **113**: 501–507
- Levine MN, Gent M, Hirsh J, Arnold A, Goodyear MD, Hryniuk W, De Pauw S (1988) The thrombogenic effect of anticancer drug therapy in women with stage II breast cancer. *N Engl J Med* **318**: 404–407
- Milsons C, Anderson GM, Weitz JI, Rak J (2007) Elevated tissue factor procoagulant activity in CD133-positive cancer cells. *J Thromb Haemost* **5**: 2550–2552
- Ottinger H, Belka C, Kozole G, Engelhard M, Meusers P, Paar D, Metz KA, Leder LD, Cyrus C, Gnoth S (1995) Deep venous thrombosis and pulmonary artery embolism in high-grade non Hodgkin's lymphoma: incidence, causes and prognostic relevance. *Eur J Haematol* **54**: 186–194
- R Development Core Team (2006) *R: A language and environment for statistical computing*. R Foundation for Statistical Computing, Vienna, Austria. ISBN 3-900051-07-0, URL <http://www.R-project.org>
- Reuben JM, Lee BN, Li C, Broglio KR, Valero V, Jackson S, Ueno NT, Krishnamurthy S, Hortobagyi GN, Cristofanilli M (2007) Genomic of circulating tumor cells in metastatic breast cancer. *J Clin Oncol* **25**: 1002S
- Silverstein MD, Heit JA, Mohr DN, Petterson TM, O'Fallon WM, Melton III LJ (1998) Trends in the incidence of deep vein thrombosis and pulmonary embolism: a 25-year population-based study. *Arch Intern Med* **158**: 585–593
- von Tempelhoff GF, Dietrich M, Hommel G, Heilmann L (1996) Blood coagulation during adjuvant epirubicin/cyclophosphamide chemotherapy in patients with primary operable breast cancer. *J Clin Oncol* **14**: 2560–2568
- Weiss RB, Tormey DC, Holland JF, Weinberg VE (1981) Venous thrombosis during multimodal treatment of primary breast carcinoma. *Cancer Treat Rep* **65**: 677–679